Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National ...

Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National Cancer Institute
18. Hagenbeek A, Eghbali H, Monfardini S, et al.: Phase III intergroup study of fludarabine phosphate
compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients
with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol 24 (10): 1590-6, 2006.
[PUBMED Abstract]
19. Herold M, Haas A, Srock S, et al.: Rituximab added to first-line mitoxantrone, chlorambucil, and
prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced
follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25 (15):
1986-92, 2007. [PUBMED Abstract]
20. Hiddemann W, Kneba M, Dreyling M, et al.: Frontline therapy with rituximab added to the combination of
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome
for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a
prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 (12): 3725-
32, 2005. [PUBMED Abstract]
21. Marcus R, Imrie K, Solal-Celigny P, et al.: Phase III study of R-CVP compared with cyclophosphamide,
vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin
Oncol 26 (28): 4579-86, 2008. [PUBMED Abstract]
22. Salles GA, Mounier N, de Guibert S, et al.: Rituximab combined with chemotherapy and interferon in
follicular lymphoma patients: final analysis of the GELA-GOELAMS FL2000 study with a 5-year followup.
[Abstract] Blood 110 (11): A-792, 2007.
23. Schulz H, Bohlius J, Skoetz N, et al.: Combined immunochemotherapy with rituximab improves overall
survival in patients with follicular and mantle cell lymphoma: updated meta-analysis results. [Abstract]
Blood 108 (11): A-2760, 2006.
24. van Oers MH, Tönnissen E, Van Glabbeke M, et al.: BCL-2/IgH polymerase chain reaction status at the
end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular
lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol 28
(13): 2246-52, 2010. [PUBMED Abstract]
25. Jacobs JP, Murray KJ, Schultz CJ, et al.: Central lymphatic irradiation for stage III nodular malignant
lymphoma: long-term results. J Clin Oncol 11 (2): 233-8, 1993. [PUBMED Abstract]
26. Mendenhall NP, Million RR: Comprehensive lymphatic irradiation for stage II-III non-Hodgkin's
lymphoma. Am J Clin Oncol 12 (3): 190-4, 1989. [PUBMED Abstract]
27. Portlock CS, Rosenberg SA: No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable
histologic types. Ann Intern Med 90(1): 10-13, 1979.
28. Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with
follicular lymphoma significantly increases event-free survival and response duration compared with the
standard weekly x 4 schedule. Blood 103 (12): 4416-23, 2004. [PUBMED Abstract]
29. Witzig TE, Vukov AM, Habermann TM, et al.: Rituximab therapy for patients with newly diagnosed,
advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer
Treatment Group. J Clin Oncol 23 (6): 1103-8, 2005. [PUBMED Abstract]
30. Hainsworth JD, Litchy S, Shaffer DW, et al.: Maximizing therapeutic benefit of rituximab: maintenance
therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a
randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23 (6): 1088-95,
2005. [PUBMED Abstract]
31. Williams ME: ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens
for patients with low tumor burden indolent non-Hodgkin's lymphoma. Curr Hematol Rep 3 (6): 395-6,
2004. [PUBMED Abstract]
32. Buske C, Hiddemann W: Rituximab maintenance therapy in indolent NHL: a clinical review. Leuk Res 30
(Suppl 1): S11-5, 2006. [PUBMED Abstract]
33. Czuczman MS, Koryzna A, Mohr A, et al.: Rituximab in combination with fludarabine chemotherapy in
low-grade or follicular lymphoma. J Clin Oncol 23 (4): 694-704, 2005. [PUBMED Abstract]
34. Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line
treatment for advanced follicular lymphoma. Blood 105 (4): 1417-23, 2005. [PUBMED Abstract]
file:///Users/mauriciolema/Documents/MLMGuias_09_LinfomaNoHodgkin.webarchive
29/09/11 6:15
Página 38 de 61